Zolpidem and Rebound Insomnia - A Double-Blind, Controlled Polysomnographic Study in Chronic Insomniac Patients
The DOI matches its Crossref record.
Abstract
In a parallel-group, placebo-controlled, polysomnography study with randomization, the possible occurrence of rebound insomnia was evaluated in 24 patients suffering from moderate to severe chronic insomnia and receiving either triazolam 0.5 mg, Zolpidem 10mg, or placebo. Treatment duration was 27 nights, followed by three placebo controlled withdrawal nights. Both drugs showed significant efficacy compared to placebo during the active treatment period. A trend toward tolerance was noted in the triazolam group but not in the Zolpidem one. The increase in total sleep time in the Zolpidem group was accompanied by an increase in the number of sleep cycles. When active treatment was discontinued, clear rebound insomnia was present in the triazolam group while it was not possible to observe any rebound in the placebo and Zolpidem groups. Subjective feelings of the patients, which were assessed by means of visual analog scales, correlated well with polysomnographic data. Our findings tend to indicate that, even after long-term treatment, Zolpidem does not induce rebound insomnia or daytime anxiety. Zusammenfassung In dieser plazebokontrollierten, in drei Behandlungsgruppen randomisierten polysomnographischen Studie wurde das Auftreten von Rebound-Schlafstörungen nach Behandlung mit entweder Triazolam 0.5 mg, Zolpidem 10 mg oder Plazebo an 24 mittel- bis schwer chronisch schlafgestörten Patienten untersucht. Die Behandlungdauer betrug 27 Nächte gefolgt von drei Entzugsnächten mit Plazebo-Behandlung. Beide aktive Behandlungen waren signifikant verschieden von Plazebo während der aktiven Behandlungsperiode. Tendenzen für Toleranzentwicklungen traten nur in der Triazolamgruppe auf, nicht jedoch in der Zolpidemgruppe. Der Anstieg der Gesamtschlafzeit in der Zolpidemgruppe war begleitet von einem Anstieg in der Anzahl von Schlafzyklen. Nach Entzug der aktiven Behandlung traten in der Triazolamgruppe eindeutige Reboundeffekte auf; keine derartigen Effekte waren in der Plazebogruppe zu beobachten. Das subjektive Empfinden der Patienten, erfaßt durch visuelle Analogskalen, korrelierte gut mit den polysomnographischen Daten. Unsere Beobachtungen weisen darauf hin, daß Zolpidem, selbst nach Langzeitbehandlung, weder Rebound-Schlafstörungen noch Tages-Angst induziert.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Sateia, M. J., Buysse, D. J., Krystal, A. D., Neubauer, D. N., & Heald, J. L. (2017) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.6470 · Cited by 1,519
Benzodiazepines and Zolpidem for Chronic Insomnia: A Meta-analysis of Treatment Efficacy
Nowell, P. D. (1997) · JAMA · doi:10.1001/jama.1997.03550240060035 · Cited by 451
Zolpidem: A Review of Its Use in the Management of Insomnia
Swainston Harrison, T., & Keating, G. M. (2005) · CNS Drugs · doi:10.2165/00023210-200519010-00008 · Cited by 323
Holm, K. J., & Goa, K. L. (2000) · Drugs · doi:10.2165/00003495-200059040-00014 · Cited by 317
Kupfer, D. J., & Reynolds, C. F. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701303360506 · Cited by 287
Metadata
- Authors
- Monti, J., Attali, P., Monti, D., Zipfel, A., de la Giclais, B., & Morselli, P.
- Venue
- Pharmacopsychiatry
- Publisher
- Georg Thieme Verlag KG
- Published
- 1994-07
- Volume
- 27
- Issue
- 04
- Pages
- 166-175
- ISSN
- 0176-3679 (ISSN-L)
- 1439-0795
- OpenAlex
- W2079328435
- Cited by
- 92
- References
- 0
- FWCI
- 10.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Zolpidem and Rebound Insomnia - A Double-Blind, Controlled Polysomnographic Study in Chronic Insomniac Patients. https://app.cochat.ai/papers/10.1055/s-2007-1014298
- The paper
- Monti, J., Attali, P., Monti, D., Zipfel, A., de la Giclais, B., & Morselli, P. (1994). Zolpidem and Rebound Insomnia - A Double-Blind, Controlled Polysomnographic Study in Chronic Insomniac Patients. Pharmacopsychiatry. https://doi.org/10.1055/s-2007-1014298
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.